ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: back pain

Rheumatology Online Educational Courses Among Key ARHP Pillars

Paul M. Adam, MSW, & Afton L. Hassett, PsyD  |  June 15, 2017

Editor’s note: The new Pillar Talk column is developed by the ARHP Executive Committee in an effort to share information about ongoing activities related to our four pillars: Education, Practice, Research and Advocacy. The ARHP Online Education Portfolio continues to evolve and grow. The Advanced Rheumatology Course (ARC) and the Fundamentals of Rheumatology Course (FRC)…

Filed under:Education & TrainingInterprofessional Perspective Tagged with:Association of Rheumatology Professionals (ARP)courseEducationonlinerheumatologistrheumatologyTechnologyTraining

The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

Simon M. Helfgott, MD  |  June 15, 2017

Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

Filed under:Biologics/DMARDsOpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:BiologicsBiosimilarsbiotechnologyCongressDNAdrug costdrug therapypatient careResearchRheumatic DiseaserheumatologistrheumatologyTreatment

Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

Susan Bernstein  |  June 14, 2017

While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…

Filed under:Practice Support Tagged with:BiologicsBiosimilarsCompliancecostsdruggenericHealthcareMedicationpatient careRheumatic DiseaserheumatologistTreatment

Rheumatologist Dr. Sandra Pagnussat Recalls Journey from Patient to Physician

Linda Childers  |  June 14, 2017

When she was in elementary school, Sandra Pagnussat, MD, began experiencing unrelenting pain and stiffness, first in her pinky and then in her other fingers. Her pediatrician diagnosed her with polyarticular juvenile idiopathic arthritis (JIA). In high school, Sandra decided to pursue a career in medicine and began taking advanced placement classes in biology and chemistry….

Filed under:Career DevelopmentConditionsOther Rheumatic ConditionsProfiles Tagged with:CareerDr. Sandra PagnussatJIAJuvenile idiopathic arthritispatient careRheumatoid arthritisrheumatologist

FDA Asks Endo to Withdraw Opana ER Opioid

Reuters Staff  |  June 10, 2017

(Reuters)—The U.S. Food and Drug Administration said on Thursday it has asked Endo International to withdraw from the market its long-lasting opioid painkiller Opana ER, sending the company’s shares down as much as 13%. “After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer…

Filed under:AnalgesicsDrug Updates

IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk

Reuters Staff  |  June 8, 2017

NEW YORK (Reuters Health)—Immunosuppressants and anti-TNF drugs do not appear to increase the risk of extracolonic cancers in patients with inflammatory bowel disease (IBD), researchers from Spain report. IBD patients face an increased risk of colon cancer, and some studies have suggested there might be an increased risk of extracolonic cancer. Dr. Maria Chaparro from…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Anti-TNFanti-TNF agentCancerIBDinflammatory bowel diseasenonmelanoma skin cancer (NMSC)

U.S. State, Local Government Lawsuits Over Opioids Face Uphill Battle

Nate Raymond  |  June 5, 2017

BOSTON (Reuters)—A growing number of U.S. states, counties and cities are filing lawsuits accusing drug companies of deceptively marketing opioid painkillers to downplay their addictiveness, but some lawyers say the industry’s highly regulated nature could pose a hurdle to their success. Ohio on Wednesday became the latest, and largest, state or local government to bring…

Filed under:AnalgesicsDrug Updates Tagged with:Legal

NSAIDs Increase MI Risk; Plus New Label Warnings for Canagliflozin

Michele B. Kaufman, PharmD, BCGP  |  May 29, 2017

NSAIDs Increase Myocardial Infarction Risk According a recent meta-analysis of real-world non-steroidal anti-inflammatory drug (NSAID) use, NSAIDs may increase the risk of acute myocardial infarction (AMI). The analysis used individual patient data meta-analysis of studies from healthcare databases in Canada, Finland and the U.K. to determine the time course for risk of AMI, as well…

Filed under:AnalgesicsDrug Updates Tagged with:canagliflozindiabetesFDAFood and Drug AdministrationheartMyocardial infarctionNonsteroidal anti-inflammatory drugs (NSAIDs)NSAIDs

Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis

Michele B. Kaufman, PharmD, BCGP  |  May 22, 2017

The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:abaloparatideFDAFood and Drug Administrationinfliximabinfliximab-abdaOsteoporosis

Optical Workings: Specialists Must Communicate to Treat Eye Disease

Richard Quinn  |  May 19, 2017

In an age of new medications for eye disease, rheumatologists and ophthalmologists must work together and communicate, says James Rosenbaum, MD. Teamwork and understanding how each specialty approaches the physical exam will aid patient care…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:eyeEye diseaseInflammatory Eye DiseaseOphthalmologistUveitis

  • « Previous Page
  • 1
  • …
  • 116
  • 117
  • 118
  • 119
  • 120
  • …
  • 163
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences